FDA Issues A Complete Response Letter For Lilly's Olanzapine LAI For Treatment Of Schizophrenia In Adults (Medical News Today) PDF Print

Eli Lilly and Company (NYSE: LLY) announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) for olanzapine long-acting injection (LAI) for acute and maintenance treatment of schizophrenia in adults. Lilly is continuing to work with the agency on the new drug application (NDA).

read more

 
Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.